{"id":"alpha-gi","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)"},{"rate":"10-20","effect":"Abdominal pain"},{"rate":"5-15","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alpha-GI drugs inhibit enzymes (alpha-glucosidases) responsible for breaking down disaccharides and complex carbohydrates into monosaccharides. By delaying glucose absorption, they reduce postprandial blood glucose spikes in patients with type 2 diabetes or impaired glucose tolerance. This mechanism helps improve glycemic control without stimulating insulin secretion.","oneSentence":"Alpha-glucosidase inhibitor that slows carbohydrate digestion and glucose absorption in the small intestine.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:01.052Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"},{"name":"Impaired glucose tolerance"}]},"trialDetails":[{"nctId":"NCT07498894","phase":"","title":"Salivary and Serum Inflammatory Biomarkers in Diabetic Nephropathy by Periodontal Status","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2024-06-10","conditions":"Diabetic Nephropathy Type 2, Type 2 Diabetes, Periodontitis","enrollment":126},{"nctId":"NCT06427798","phase":"PHASE1, PHASE2","title":"Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-07","conditions":"Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma","enrollment":66},{"nctId":"NCT03342196","phase":"PHASE2","title":"Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2018-03-21","conditions":"Leukemia","enrollment":40},{"nctId":"NCT06268717","phase":"NA","title":"GI Alpha-Gal Study","status":"RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-10-17","conditions":"Alpha-Gal Syndrome, Irritable Bowel Syndrome, Diarrhea","enrollment":30},{"nctId":"NCT02312817","phase":"NA","title":"RCT of Screening Strategies Among Patients at High Risk for Developing HCC in a Safety-net Health System","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2014-12","conditions":"Carcinoma, Hepatocellular, Liver Neoplasms","enrollment":1800},{"nctId":"NCT05142137","phase":"NA","title":"Novel Alpha Glucan GI Tolerability Study (Loris Chronic)","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2021-08-16","conditions":"Healthy Volunteers","enrollment":24},{"nctId":"NCT03420976","phase":"EARLY_PHASE1","title":"Novel Supplement-based Therapy for the Treatment of Small Intestinal Bacterial Overgrowth","status":"WITHDRAWN","sponsor":"Atrium Innovations","startDate":"2017-12-07","conditions":"Small Intestinal Bacterial Overgrowth","enrollment":""},{"nctId":"NCT01925950","phase":"PHASE2","title":"Study of orBec® as Monotherapy in the Treatment of Patients With Upper GI Symptoms Caused by Chronic Graft Versus Host Disease (GVHD)","status":"TERMINATED","sponsor":"Soligenix","startDate":"2013-12","conditions":"Chronic Gastrointestinal Graft vs Host Disease","enrollment":2},{"nctId":"NCT00019474","phase":"PHASE2","title":"Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"1998-03","conditions":"Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor","enrollment":60},{"nctId":"NCT02431377","phase":"NA","title":"Acceptability and GI Tolerance of an Alpha-lactalbumin-enriched Formula","status":"COMPLETED","sponsor":"Société des Produits Nestlé (SPN)","startDate":"2015-04","conditions":"Infant Formula Intolerance","enrollment":40},{"nctId":"NCT01940965","phase":"PHASE3","title":"Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-09","conditions":"Type 2 Diabetes Mellitus","enrollment":294},{"nctId":"NCT01468181","phase":"PHASE3","title":"A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-11","conditions":"Type 2 Diabetes Mellitus","enrollment":394},{"nctId":"NCT02253628","phase":"NA","title":"The Acute Effect of Coffee Consumption on Stomach, Self-reported Gastrointestinal Symptoms and Stress.","status":"COMPLETED","sponsor":"Agricultural University of Athens","startDate":"2014-02","conditions":"Stress, Signs and Symptoms, Digestive, Blood Pressure","enrollment":40},{"nctId":"NCT01204294","phase":"PHASE3","title":"Comprehensive Add on Study in Japan","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2010-09","conditions":"Diabetes Mellitus, Type 2","enrollment":574}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":169,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"alpha-GI","genericName":"alpha-GI","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alpha-glucosidase inhibitor that slows carbohydrate digestion and glucose absorption in the small intestine. Used for Type 2 diabetes mellitus, Impaired glucose tolerance.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}